https://www.selleckchem.com/EGFR(HER).html
Interestingly, CHK1 inhibition showed the single-agent antitumor activity in ER+/PR+/HER2- breast cancer which was mediated by the cyclin dependent kinase inhibitor 1A (p21), kinesin family member 11 (Eg5) and cell surface death receptor (Fas). Conclusions CHK1's variable role determines the application of CHK1 inhibition in breast cancer with ER/PR heterogeneity. © The author(s).Neoadjuvant chemotherapy has been used increasingly in patients with early-stage or locally advanced breast carcinoma, and has been recommended as a general approach
Like
Comment
Share
